Compare · GILD vs VRTX
GILD vs VRTX
Side-by-side comparison of Gilead Sciences Inc. (GILD) and Vertex Pharmaceuticals Incorporated (VRTX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. GILD focuses on Biotechnology: Biological Products (No Diagnostic Substances), while VRTX focuses on Biotechnology: Pharmaceutical Preparations.
- GILD is the larger of the two at $206.55B, about 1.6x VRTX ($132.01B).
- Over the past year, GILD is up 33.2% and VRTX is up 23.3% - GILD leads by 10.0 points.
- GILD has been more active in the news (22 items in the past 4 weeks vs 12 for VRTX).
- Both have 25 recent analyst ratings on file.
- Company
- Gilead Sciences Inc.
- Vertex Pharmaceuticals Incorporated
- Price
- -
- -
- Market cap
- $206.55B
- $132.01B
- 1M return
- +8.45%
- -0.77%
- 1Y return
- +33.25%
- +23.26%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1992
- 1991
- News (4w)
- 22
- 12
- Recent ratings
- 25
- 25
Gilead Sciences Inc.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 12 years of age or older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator, or CFTR, gene. Its pipeline includes Pipeline for Alpha-1 antitrypsin deficiency that is in Phase 2 clinical trial; VX-864, a second investigational small molecule corrector for the treatment of AAT deficiency, which is in Phase 1 clinical trial; and VX-147 that completed a Phase 1 clinical trial for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. Vertex Pharmaceuticals Incorporated has collaborations with CRISPR Therapeutics AG; Arbor Biotechnologies, Inc.; Moderna, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany; X-Chem, Inc.; Janssen Pharmaceuticals, Inc.; Merck KGaA; Kymera Therapeutics; Ribometrix, Inc.; Molecular Templates, Inc.; and Affinia Therapeutics, as well as a strategic research collaboration and licensing agreement with Obsidian Therapeutics, Inc. for the discovery of novel therapies that regulate gene editing for the treatment of serious diseases. The company was founded in 1989 and is headquartered in Boston, Massachusetts.
Latest GILD
- Chief Comm & Corp Aff Officer Johanna Mercier exercised 25,000 shares at a strike of $72.34 and sold $4,775,527 worth of shares (28,000 units at $170.55) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 110,684 units (SEC Form 4)
- Chief Financial Officer Andrew D Dickinson sold $514,410 worth of shares (3,000 units at $171.47) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 158,096 units (SEC Form 4)
- Kernal Bio Announces Strategic Investment from IFLI and Leadership Appointments
- Gilead Expands Access to Investigational Obeldesivir for Ebola Bundibugyo Virus Disease Through Voluntary Licensing
- Director Kramer Kelly A. exercised 10,376 shares at a strike of $66.92 and sold $1,761,437 worth of shares (10,376 units at $169.76) as part of a pre-agreed trading plan (SEC Form 4)
- A Run of FDA Target Dates Fills the Biotech Calendar From Late November to Year End
- EVP Gen Counsel, Legal & Comp Cain Wettan Keeley M sold $557,810 worth of shares (3,399 units at $164.11) as part of a pre-agreed trading plan, decreasing direct ownership by 39% to 5,360 units (SEC Form 4)
- Gabelli Releases Agenda for 8th Annual Healthcare Symposium
- Chairman & CEO O'Day Daniel Patrick exercised 112,429 shares at a strike of $72.34 and sold $19,693,439 worth of shares (112,429 units at $175.16) as part of a pre-agreed trading plan (SEC Form 4)
- New Data Show Twice-Yearly Lenacapavir Achieved Nearly Twice the One-Year Persistence of Daily Oral F/TDF in HIV Prevention
Latest VRTX
- Director Nancy Thornberry sold $547,860 worth of shares (1,000 units at $547.86) as part of a pre-agreed trading plan, decreasing direct ownership by 47% to 1,109 units (SEC Form 4)
- Director Sangeeta N. Bhatia sold $148,470 worth of shares (271 units at $547.86) as part of a pre-agreed trading plan, decreasing direct ownership by 6% to 4,653 units (SEC Form 4)
- EVP, CO & FO Wagner Charles F Jr sold $8,374,741 worth of shares (15,286 units at $547.87) as part of a pre-agreed trading plan, decreasing direct ownership by 32% to 31,764 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Vertex Pharmaceuticals Incorporated
- A Run of FDA Target Dates Fills the Biotech Calendar From Late November to Year End
- CEO & President Kewalramani Reshma sold $6,307,135 worth of shares (11,866 units at $531.53) as part of a pre-agreed trading plan, decreasing direct ownership by 12% to 86,471 units (SEC Form 4)
- Raised Outlooks and a Cancer Approval Arrive in the Middle of Medicare Open Enrollment
- Stocks Surged Across the Board Today, and Biotech Brought Its Own Earnings Story
- Vertex to Participate in Upcoming Investor Conferences
- SEC Form 10-Q filed by Vertex Pharmaceuticals Incorporated